Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

Open access
Rosenzwajg, Michelle, Churlaud, Guillaume, Mallone, Roberto, Six, Adrien, Dérian, Nicolas, Chaara, Wahiba, Lorenzon, Roberta, Long, S. Alice, Buckner, Jane H., Afonso, Georgia, Pham, Hang-Phuong, Hartemann, Agnès, Yu, Aixin, Pugliese, Alberto, Malek, Thomas R., Klatzmann, David·2015·Journal of Autoimmunity

Abstract

Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in CD4+Foxp3+ and CD8+Foxp3+ Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaut.2015.01.001

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Metadata

Authors
Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., Lorenzon, R., Long, S. A., Buckner, J. H., Afonso, G., Pham, H.-P., Hartemann, A., Yu, A., Pugliese, A., Malek, T. R., & Klatzmann, D.
Venue
Journal of Autoimmunity
Publisher
Elsevier BV
Published
2015-04
Volume
58
Pages
48-58
ISSN
0896-8411 (ISSN-L)
OpenAlex
W2147557220
Cited by
257
References
64
FWCI
11.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. https://app.cochat.ai/papers/10.1016/j.jaut.2015.01.001
The paper
Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., Lorenzon, R., Long, S. A., Buckner, J. H., Afonso, G., Pham, H.-P., Hartemann, A., Yu, A., Pugliese, A., Malek, T. R., & Klatzmann, D. (2015). Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2015.01.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.